Hujialiang

Prof. Jialiang Hu is one member of the Jiangsu Engineering Center for the Discovery and Evaluation of Synthetic Peptide Drugs. His Research work focuses on the fields of inflammation, tumors, pulmonary fibrosis, and autoimmune diseases.

A polypeptide library has been designed and synthesized, from which MMP-9 polypeptide inhibitors with independent intellectual property rights have been screened out. Furthermore, a polypeptide P2 with antitumor activity has been designed and synthesized. Research has shown that P2 exhibits excellent activity in both acute inflammation and antitumor aspects. National invention patents have been applied for and obtained. Long-acting polypeptide P2 has also been developed, including PEG modification of polypeptide P2, nanoparticles containing polypeptide P2, and the research and development of ointments containing three active ingredients.

The researcher has successively presided over 7 major national science and technology projects and participated in 7 international cooperation projects. He has published 39 SCI papers and applied for 7 patents, all of which have been authorized. He was awarded the First Prize of Jiangsu Pharmaceutical Science and Technology Progress Award (second author) in 2014, the Second Prize of Jiangsu Pharmaceutical Science and Technology Progress Award (second author) in 2019, and the Second Prize of China Industry-University-Research Cooperation Innovation Achievement Award (second author) in 2019.

1. Wang X, Wang Y, Hu J*, Xu H*. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity. Cancer Medicine. 2021 Mar;10(6):2125-2136 (IF=3.491)

2. Li Dongping, Wang Ying, Tang Lu, Xinrong Jin, Chunlei Xia, Hanmei Xu*, Jialiang Hu*. CD200-CD200R1 signalling attenuates imiquimod-induced psoriatic inflammation by inhibiting the activation of skin inflammatory macrophages.[J] .Int. Immunopharmacol., 2020, 78: 106046 (IF=9.3)

3. Li Dongping, Wang Ying, Jin Xinrong, Hu Die, Xia Chunlei, Xu Hanmei*, Hu Jialiang*. NK cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice.[J]. J Neuroinflammation, 2020, Apr 22;17(1):126 (IF=5.6)

4. Pei D#, Hu J#, Rao C, Yu P, Xu H, Wang J. Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein. Int J Med Sci. 2019;16(7):1032-1041 (IF=3.19)

5. Chi X, Yang P, Zhang E, Gu J, Xu H, Li M, Gao X, Li X, Zhang Y, Xu H*, Hu J*. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12. Cancer Med. 2019 Aug;8(10):4753-4765 (IF=2.89)

6. Sun Q#, Hu J#, Yu P, Zhu Z, Yu R, Ge C, Li C, Wu G, Lin B, Liu G, Liu M, Bian H, Xu H, Jia S. Peptide PD29 treats bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β/smad signaling pathway. Exp Lung Res. 2019;45(5-6):123-134. (IF=1.49)

7. Abbas AB, Lin B, Liu C, Morshed A, Hu J*, Xu H*. Design and synthesis of a PD-1 binding peptide and its anti-tumor activity evaluation. Int J Mol Sci. 2019 Jan 29;20(3). pii: E572. (IF=4.90)

8. Morshed A, Abbas AB, Hu J*, Xu H*. Shedding New Light on The Role of ανβ3 and α5β1 integrins in Rheumatoid Arthritis. Molecules. 2019 Apr 18;24(8). pii: E1537. (IF=4.19)

9. Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi, Sun Q, Zhang S, Hu J*, Xu H*. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018, 11(1):102 (IF=29.5)

10. Mengwei Li, Yanzhen Han, Haoze Zhou, Xin Li, Chenyu Lin, Erhao Zhang, Xiaowei Chi, Jialiang Hu*, Hanmei Xu*. Transmembrane protein 170B is a novel breast tumorigenesis suppressor gene that inhibits the Wnt/β-catenin pathway. Cell Death and Disease 2018, 9(2):91 (IF=8.10)

11. Zhang E, Gu J, Xue J, Lin C, Liu C, Li M, Hao J, Setrerrahmane S, Chi X, Qi W, Hu J*, Xu H*. Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide. J Hematol Oncol. 2018 Mar 20;11(1):44. (IF=29.5)

Huang R, Li J, Wang Y, Zhang L, Ma X, Wang H, Li W, Cao X, Xu H*, Hu J*. The Protective Effect of a Long-Acting and Multi-Target HM-3-Fc Fusion Protein in Rheumatoid Arthritis. Int J Mol Sci. 2018 Sep 10;19(9). pii: E2683. (IF=4.90)

1. Double First-Class Construction Project Prospective Basic Research Special Project of China Pharmaceutical University, Establishment of a Novel Polypeptide Technology Platform Derived from Non-coding RNA and Discovery of New Antitumor Targets (CPU2022QZ02), 2022.6-2025.6;

2. Double First-Class Construction Project New Drug Cultivation Project of China Pharmaceutical University, CPU2018PZH03, Peptide Drug Pagai Antegen, 2018.1-2020.12;

3. Interdisciplinary Collaborative Innovation Team of Jiangsu Collaborative Innovation Center of Biomedical Pharmaceutical, Research on Innovative Peptide Drug Discovery, 2017.1-2017.12.

1. the First Prize of Jiangsu Pharmaceutical Science and Technology Progress Award (second author) in 2014,

2. the Second Prize of Jiangsu Pharmaceutical Science and Technology Progress Award (second author) in 2019,

3. the Second Prize of China Industry-University-Research Cooperation Innovation Achievement Award (second author) in 2019.